Supplementary Figure 3 from A CDCA2 - MYC positive feedback loop controls cancer cells survival

A) Kaplan–Meier curve (survival probability in months) of neuroblastoma patients expressing low (red curve) or high (blue curve) levels of RIF1 (Kocak cohort) (GSE45547) (55). B) Kaplan–Meier curve (survival probability in months) of neuroblastoma patients expressing low (red curve) or high (blue curve) levels of PPP1R7 (Kocak cohort) (GSE45547) (55). C) Kaplan–Meier curve (survival probability in months) of neuroblastoma patients expressing low (red curve) or high (blue curve) levels of PPP1R8 (Kocak cohort) (GSE45547) (55). D) MYCN chromatin immunoprecipitation sequencing profiles at the CDCA2 locus in SHEP-T21N (GSM2113542) and KELLY cell lines (GSM2113526). E) MYCN chromatin immunoprecipitation sequencing profiles at the PNUTS locus in SHEP-T21N (GSM2113542) and Kelly cell lines (GSM2113526). F) Western blot analyses of SHEP-T21N, LAN-1, KELLY and IMR32 cell lines. The blots were probed with anti-alpha tubulin or anti-GAPDH and with anti-CDCA2, anti-MYCN-total antibodies. The images were acquired with a LICOR Imaging system in the linear range for quantification purposes. G) Correlation of MYCN to CDCA2 normalised protein levels from (F).